Does Xeris Pharmaceuticals Inc. (NASDAQ: XERS) Still Need To Convince Analysts? – Stocks Register
Home  »  Finance   »  Does Xeris Pharmaceuticals Inc. (NASDAQ: XERS) Sti...

Does Xeris Pharmaceuticals Inc. (NASDAQ: XERS) Still Need To Convince Analysts?

Xeris Pharmaceuticals Inc. (NASDAQ:XERS) traded at $2.66 at last check on Monday, September 27, made an upward move of 6.86% on its previous day’s price.

Looking at the stock we see that its previous close was $2.49 and the beta (5Y monthly) reads 1.83 with the day’s price range being $2.465 – $2.57. In terms of its 52-week price range, XERS has a high of $7.94 and a low of $2.16. The company’s stock has lost about -9.78% over that past 30 days.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


Xeris Pharmaceuticals Inc. has a market cap of $170.89 million and is expected to release its quarterly earnings report on Aug 09, 2021 – Aug 13, 2021. Estimates by analysts give the company expected earnings per share (EPS) of -$0.36, with the EPS growth for the year raised at -$1.4 for 2021 and -$0.74 for next year. These figures represent 34.60% and 47.10% growth in EPS for the two years respectively.

Analysts tracking the company’s growth have also given it a consensus growth in revenue estimated at $11.01 million, with a low of $9.21 million and a high of $12.83 million. The median projection represents growth squeezing down to 17.10% compared to sales growth for the corresponding quarter a year ago. According to analyst consensus estimates figures, the company’s yearly revenue forecast for 2021 is expected to hit $39.38 million, or 92.70% up from figures reported last year.

There have been no upward and no downward revisions for the stock’s EPS in last 7 days, something that reflects the nature of company’s price movement in short term. On the other hand, looking at the outlook for the XERS stock, short term indicators assign the stock an average of 50% Sell, while medium term indicators assign it an average of 100% Sell. Long term indicators on average place the stock in the category of 100% Sell.

Based on estimates by 3 analysts, where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, 0 have rated the Xeris Pharmaceuticals Inc. (XERS) stock as a Hold, while 3 rate it as a Buy. 0 analyst(s) rate it as overweight while 0 of them rated it as underweight, whereas 0 suggest the stock as a Sell. The stock has an overall rating of Buy and investors could take advantage and scoop up stock of the company.

Looking further, we note the current price level is 1.52% off its SMA20 and -3.00% from its 50-day simple moving average. The RSI (14) is pointing at 51.81 while the volatility over the past week is 5.64% and jumps to 5.51% over the past one month. The average price target for the stock over the next 12 months is $8.33, with the estimates having a low of $8.00 and a high of $9.00. These price ends are -200.75% and -238.35% off the today’s price level respectively, although investors could be excited at the prospect of a -200.75% if the XERS share price touches on the median price of $8.00.

Coming back to Xeris Pharmaceuticals Inc. (NASDAQ:XERS), we note that the average 3-month trading volume was 3.72 million, while that of the preceding 10-day period stands at 0.95 million. Current shares outstanding are 66.37 million.

>> 7 Top Picks for the Post-Pandemic Economy <<

The insiders hold 1.00% of the company’s shares while institutions hold 48.10%. The data shows that short shares as of Jul 29, 2021, stood at 5.38 million at a short ratio of 3.34. This represents a 8.10% short interest in shares outstanding on Jul 29, 2021. Shares short fall in July from the previous month at 13.4 million. Investors should be excited about this stock as its upside potential is great, with today’s price pushing the stock -49.39% down in year-to-date price movement.

Leave a Comment

Your email address will not be published. Required fields are marked *

Related Posts

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam